NeuroPace(US:NPCE)2026-03-03 22:32Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $26.6 million, representing a 24% year-over-year growth compared to $21.5 million in the prior year quarter [5][22] - RNS System revenue was $22.4 million, up 26% year-over-year, reflecting strong performance in the core business [6][22] - Gross margin improved to over 77%, up approximately 200 basis points year-over-year, driven by manufacturing efficiencies [9][24] - Adjusted EBITDA was positive at $900,000 in the fourth quarter, marking a $1.9 million improvement compared to the prior year quarter [28] Business Line Data and Key Metrics Changes - The majority of revenue growth continues to come from Level 4 centers, with RNS growth in the second half of 2025 at 29% [8] - Service revenue tied to data collaborations totaled approximately $890,000 in the fourth quarter [22] - Revenue from DIXI Medical was approximately $3 million, representing a decline of 4% compared to the fourth quarter of 2024 [22] Market Data and Key Metrics Changes - The company is focused on expanding access to RNS therapy through community pathways and referral pathways, which are contributing to growth [6][8] - The adult focal epilepsy market remains a significant opportunity, with ongoing efforts to deepen adoption and utilization [6][39] Company Strategy and Development Direction - The company aims to grow a minimum of 20% in its core RNS business with the current adult focal epilepsy indication [9] - Strategic investments are being made in the commercial organization, including sales representative additions and nurse navigator resources [11][20] - The company is pursuing an expanded indication for the RNS System in idiopathic generalized epilepsy (IGE) and has submitted a PMA supplement to the FDA [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory and the potential for a transformational 2026 [10][20] - The company is optimistic about the upcoming approval for IGE and the associated market opportunities [41][55] - Management highlighted the importance of ongoing investments in product development and clinical programs to enhance the RNS System's capabilities [42] Other Important Information - The company plans to report DIXI-related financial results as discontinued operations starting in Q1 2026 [30][31] - Full year 2026 revenue guidance is reiterated at $98 million-$100 million, excluding contributions from DIXI [32] Q&A Session Summary Question: Can you provide details on the timeline from approval to revenue collection for the generalized opportunity? - Management indicated that extending coverage in the private payer community is crucial and that preparations are already underway [46] Question: What is the magnitude of pricing impact on RNS growth in the fourth quarter? - Management noted consistent mid-single digit pricing increases annually, with no significant changes in Q4 [61] Question: What are the current dynamics regarding capacity across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being utilized to streamline patient flow [70][72] Question: Can you elaborate on the Seizure ID opportunity and its implementation? - Seizure ID will be part of the RNS System offering, aimed at improving clinician efficiency without additional costs [79]